Lakefront Biotherapeutics American Depositary Shares
LKFT
85 hedge funds and large institutions have $494M invested in Lakefront Biotherapeutics American Depositary Shares in 2024 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 38 increasing their positions, 18 reducing their positions, and 9 closing their positions.
111% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 18
33% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 9
4% more funds holding
Funds holding: 82 → 85 (+3)
0.84% less ownership
Funds ownership: 31.09% → 30.25% (-0.84%)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
25% less capital invested
Capital invested by funds: $660M → $494M (-$166M)
86% less call options, than puts
Call options by funds: $230K | Put options by funds: $1.66M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PM
Prosight Management
Dallas,
Texas
|
+$11.9M |
| 2 |
NM
Newtyn Management
New York
|
+$3.8M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$3.76M |
| 4 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$2.63M |
| 5 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$2.59M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$36.5M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
-$8.35M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$3.68M |
| 4 |
SBH
Segall Bryant & Hamill
Chicago,
Illinois
|
-$1.96M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.73M |
LKFT Hedge Fund Activity: Q2 2024 in Review
85 of the 6,927 institutional investors tracked by Wall St. Rank reported a position in Lakefront Biotherapeutics American Depositary Shares (LKFT) for Q2 2024, worth a combined $494M — down 25% from $660M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new LKFT positions and 9 closed out — a net gain of 3 holders — while 38 added to existing stakes and 18 trimmed.
The largest buyer was Prosight Management, adding an estimated $11.9M. The largest seller was Fidelity Investments, cutting an estimated $36.5M.
- 85 institutional investors held Lakefront Biotherapeutics American Depositary Shares (LKFT) as of Q2 2024, up from 82 in Q1 2024.
- Funds reported $494M of Lakefront Biotherapeutics American Depositary Shares stock for Q2 2024, down 25% quarter-over-quarter.
- 12 funds opened new Lakefront Biotherapeutics American Depositary Shares positions in Q2 2024 and 9 closed out, a net change of +3 holders.
- The largest Lakefront Biotherapeutics American Depositary Shares buyer in Q2 2024 was Prosight Management, an estimated $11.9M added.
- The largest Lakefront Biotherapeutics American Depositary Shares seller in Q2 2024 was Fidelity Investments, an estimated $36.5M sold.
Based on aggregated 13F filings for Q2 2024.